Inactive Instrument

MYOS Corp Share Price OTC Bulletin Board

Stocks

US5540511020

End-of-day quote
- USD - Intraday chart for MYOS Corp

Valuation: MYOS Corp

Market Cap 7.25M 6.47M 5.95M 5.4M 10.24M 679M 10.49M 71.2M 28.38M 364M 27.2M 26.62M 1.15B P/E 2021
-1.04x
P/E 2022 -0.41x
Enterprise Value 2.88M 2.57M 2.36M 2.15M 4.07M 270M 4.17M 28.27M 11.27M 144M 10.8M 10.57M 455M EV / Sales 2021
1.74x
EV / Sales 2022 0.46x
Free-Float
-
Yield 2021 *
-
Yield 2022 -

Financials

2021 2022
Net sales 22.13M 19.75M 18.18M 16.5M 31.26M 2.07B 32.04M 217M 86.66M 1.11B 83.06M 81.28M 3.5B 43.11M 38.48M 35.41M 32.14M 60.9M 4.04B 62.41M 424M 169M 2.16B 162M 158M 6.81B
Net income -43.82M -39.11M -35.99M -32.66M -61.9M -4.11B -63.44M -431M -172M -2.2B -164M -161M -6.93B -47.62M -42.5M -39.11M -35.5M -67.27M -4.46B -68.94M -468M -186M -2.39B -179M -175M -7.53B
Net Debt -7.44M -6.64M -6.11M -5.55M -10.51M -698M -10.77M -73.12M -29.14M -373M -27.93M -27.34M -1.18B -4.37M -3.9M -3.59M -3.26M -6.17M -410M -6.33M -42.93M -17.11M -219M -16.4M -16.05M -691M
Logo MYOS Corp
MYOS RENS Technology Inc. is focused on the discovery, development and commercialization of nutritional ingredients, functional foods, and other technologies for maintaining or improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle-related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement that has been shown in clinical studies to temporarily decrease the levels of serum myostatin, MYO-T12, a formulation containing Fortetropin. Fortetropin is the Company's all-natural food ingredient clinically shown to enhance muscle size, lean body mass and strength as part of resistance training in humans. Fortetropin is made from fertilized chicken egg yolks using a process that retains the biological integrity and bioactivity of the product.
Employees
-
Sector
-